TRAX — First Tracks Biotherapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 2091349 ·
Last close
$17.06
Market Cap
$595.09M
52W High
$26.80
52W Low
$14.79
ADV30
455,878
Next earnings
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -52,811,000 -50,484,000 290,576,000 248,469,000 33,112,000
Mar 2025 0 -51,280,000 -47,196,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-77,567,000
Investing CF
$49,830,000
Financing CF
$13,567,000
CapEx
$-52,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.81
As of
2026-05-20

Balance + Analyst (yfinance extras)

Retained Earnings
Inventory
Receivables
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts
7

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 0 -181,101,000 -163,705,000 441,891,000 50,295,000 -125,806,000
Dec 2023 0 -118,461,000 -106,150,000 444,109,000 34,260,000 -93,004,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-3.18

Peers — same industry

TickerNameMarket CapLastDaily %
VREOF Vireo Growth Inc. $598.52M $0.44
ZVRA ZEVRA THERAPEUTICS, INC. $610.07M $10.32
GYRE GYRE THERAPEUTICS, INC. $576.35M $5.94
ARVN ARVINAS, INC. $575.53M $8.92
ALT Altimmune, Inc. $569.81M $2.93

News headlines (Yahoo Finance, 1h cache)

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
2026-05-21 20:15 · Yahoo
How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets
2026-05-15 14:18 · Yahoo
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 20:15 · Yahoo
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:15 · Yahoo
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
2026-05-10 23:13 · Yahoo
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
2026-04-20 13:15 · Yahoo
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares
2026-03-27 13:58 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.